Table 1

Characteristics of sequenced participants at enrolment

ASPREE
N=13 131 (mean age 75 years)
Female sex—no. (%)7056 (54)
Age in years—no. (%)
 70–747894 (60)
 75–793406 (26)
 ≥801831 (14)
Race or ethnic group*—no. (%)
 White/Caucasian12 953 (99)
 Other178 (1)
Obese (BMI ≥30 kg/m2)† (%)28
Current smoking (%)4
Statin use‡ (%)33
Heart, stroke or vascular disease§ (%)0
Serum low-density lipoprotein cholesterol—mean, mg/dL119
Serum total cholesterol—mean, mg/dL204
  • Sequenced individuals were Australian participants enrolled in the ASPREE clinical trial, aged 70 years and older (average age 75 years), without a previous diagnosis of cardiovascular disease events, dementia, permanent physical disability or current diagnosis of life-threatening cancer. Most were white/Caucasian and 54% were female.

  • *Self-report.

  • †Obese was defined as body mass index (weight (kg)/height (m2)) of ≥30.

  • ‡Anatomical Therapeutic Chemical code C10 (lipid-modifying agents).

  • §Baseline characteristics of participants in the ASPREE study.14

  • ASPREE, ASPirin in Reducing Events in the Elderly.